免疫功能低下个体中的mRNA疫苗加强针与免疫系统反应受损：一篇叙述性综述
mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review.
作者信息
Boretti Alberto
机构信息
Melbourne Institute of Technology, The Argus, 288 La Trobe St, Melbourne, VIC 3000, Australia.
出版信息
Clin Exp Med. 2024 Jan 27;24(1):23. doi: 10.1007/s10238-023-01264-1.
Abstract
Over the last 24 months, there has been growing evidence of a correlation between mRNA COVID-19 vaccine boosters and increased prevalence of COVID-19 infection and other pathologies. Recent works have added possible causation to correlation. mRNA vaccine boosters may impair immune system response in immune compromised individuals. Multiple doses of the mRNA COVID-19 vaccines may result in much higher levels of IgG 4 antibodies, or also impaired activation of CD4 + and CD8 + T cells. The opportunity for mRNA vaccine boosters to impair the immune system response needs careful consideration, as this impacts the cost-to-benefit ratio of the boosters' practice.
摘要
在过去24个月里，越来越多的证据表明，新冠病毒mRNA疫苗加强针与新冠病毒感染率上升及其他病症之间存在关联。最近的研究在这种关联的基础上增加了可能的因果关系。mRNA疫苗加强针可能会损害免疫功能低下个体的免疫系统反应。多剂新冠病毒mRNA疫苗可能会导致IgG 4抗体水平大幅升高，或者也会损害CD4 +和CD8 + T细胞的激活。mRNA疫苗加强针损害免疫系统反应的可能性需要仔细考虑，因为这会影响加强针接种做法的成本效益比。
相似文献
1
mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review.
Clin Exp Med. 2024 Jan 27;24(1):23. doi: 10.1007/s10238-023-01264-1.
2
Low switched memory B cells are associated with no humoral response after SARS-CoV-2 vaccine boosters in kidney transplant recipients.
Front Immunol. 2023 Oct 24;14:1202630. doi: 10.3389/fimmu.2023.1202630. eCollection 2023.
3
Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.
Front Immunol. 2025 Jan 22;16:1526444. doi: 10.3389/fimmu.2025.1526444. eCollection 2025.
4
Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters: a case report.
J Med Case Rep. 2024 Dec 20;18(1):631. doi: 10.1186/s13256-024-04889-2.
5
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20.
6
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9.
7
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
J Infect. 2022 Jun;84(6):795-813. doi: 10.1016/j.jinf.2022.04.018. Epub 2022 Apr 9.
8
Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review.
Medicina (Kaunas). 2024 Feb 25;60(3):385. doi: 10.3390/medicina60030385.
9
Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.
J Clin Immunol. 2022 Aug;42(6):1137-1150. doi: 10.1007/s10875-022-01296-4. Epub 2022 Jun 17.
10
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lancet Infect Dis. 2023 Sep;23(9):1007-1019. doi: 10.1016/S1473-3099(23)00295-5. Epub 2023 Jun 19.
引用本文的文献
1
Cytogenetic Alterations Observed in Exfoliative Cells of the Tongue and Oral Mucosa of SARS-CoV-2-Vaccinated Patients: Report of Two Cases and a Brief Literature Review.
Rev Soc Bras Med Trop. 2025 Jun 2;58:e008042025. doi: 10.1590/0037-8682-0008-2025. eCollection 2025.
2
Diagnostic and Therapeutic Challenges in Lyme Disease and Co-Infections: Unraveling Neuropsychiatric and Neurological Complexities-A Comprehensive Case Series Analysis.
Integr Med (Encinitas). 2025 Jun;24(3):10-27.
3
Jembrana disease in Indonesia: An updated review.
Open Vet J. 2025 Mar;15(3):1091-1100. doi: 10.5455/OVJ.2025.v15.i3.3. Epub 2025 Mar 31.
4
The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status.
Iran J Med Sci. 2025 Feb 1;50(2):61-68. doi: 10.30476/ijms.2024.104003.3744. eCollection 2025 Feb.
5
Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters.
bioRxiv. 2025 Jan 9:2025.01.08.631842. doi: 10.1101/2025.01.08.631842.
6
Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2.
Vaccines (Basel). 2024 Dec 22;12(12):1444. doi: 10.3390/vaccines12121444.
7
A comprehensive review of paratuberculosis in animals and its implications for public health.
Open Vet J. 2024 Nov;14(11):2731-2744. doi: 10.5455/OVJ.2024.v14.i11.2. Epub 2024 Nov 30.
8
Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2363016. doi: 10.1080/21645515.2024.2363016. Epub 2024 Jun 5.
9
Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review.
Medicina (Kaunas). 2024 Feb 25;60(3):385. doi: 10.3390/medicina60030385.
本文引用的文献
1
Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine.
Open Forum Infect Dis. 2023 Apr 19;10(6):ofad209. doi: 10.1093/ofid/ofad209. eCollection 2023 Jun.
2
IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein.
Vaccines (Basel). 2023 May 17;11(5):991. doi: 10.3390/vaccines11050991.
3
COVID-19, post-acute COVID-19 syndrome (PACS, "long COVID") and post-COVID-19 vaccination syndrome (PCVS, "post-COVIDvac-syndrome"): Similarities and differences.
Pathol Res Pract. 2023 Jun;246:154497. doi: 10.1016/j.prp.2023.154497. Epub 2023 May 3.
4
Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
Ann Intern Med. 2023 Apr;176(4):496-504. doi: 10.7326/M22-1286. Epub 2023 Apr 4.
5
Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.
Vaccine. 2023 Apr 24;41(17):2754-2760. doi: 10.1016/j.vaccine.2023.03.031. Epub 2023 Mar 21.
6
Viral Population Heterogeneity and Fluctuating Mutational Pattern during a Persistent SARS-CoV-2 Infection in an Immunocompromised Patient.
Viruses. 2023 Jan 19;15(2):291. doi: 10.3390/v15020291.
7
Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population.
Pathogens. 2023 Feb 2;12(2):233. doi: 10.3390/pathogens12020233.
8
Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination.
Sci Immunol. 2023 Jan 27;8(79):eade2798. doi: 10.1126/sciimmunol.ade2798.
9
Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice.
iScience. 2022 Dec 22;25(12):105479. doi: 10.1016/j.isci.2022.105479. Epub 2022 Nov 2.
10
Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.
J Autoimmun. 2022 Oct;132:102898. doi: 10.1016/j.jaut.2022.102898. Epub 2022 Aug 24.
Zotero 插件